Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
US Department of Justice
Argus Health

Generated: June 24, 2018

DrugPatentWatch Database Preview

Claims for Patent: 8,501,158

« Back to Dashboard

Summary for Patent: 8,501,158
Title:Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
Abstract: Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL/sec to less than 1 mL/min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.
Inventor(s): Groman; Ernest V. (Brookline, MA), Paul; Kenneth G. (Holliston, MA), Frigo; Timothy B. (Waltham, MA), Bengele; Howard (Canton, MA), Lewis; Jerome M. (Mewton, MA)
Assignee: AMAG Pharmaceuticals, Inc. (Lexington, MA)
Application Number:12/963,308
Patent Claims: 1. A method of treating a patient in need of an iron supplement, comprising intravenously administering to said patient a unit dose of an autoclaved pharmacological composition at a rate of about 1 mL/sec, wherein the composition comprises particles of a superparamagnetic iron oxide coated a carboxymethylasted reduced dextran having between about 1100 micromoles and about 1500 micromoles carboxyl per gram of carboxymethylated reduced dextran, wherein the reduced dextran has an average molecular weight of about 10 kDa, wherein the particles have a diameter between about 10 nm and 50 nm; and wherein the unit dose has about 500 mg to 600 mg of iron.

2. The method of claim 1, wherein the pharmacological composition has a free iron concentration of less than about 0.1% as determined by atomic absorption spectroscopy on a sample of the pharmacological composition filtered through a 30 K molecular weight cutoff micropartition membrane filter.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Federal Trade Commission
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.